Alqudah Sondos M, Hailat Mohammad, Zakaraya Zainab, Abu Dayah Alaa Azeez, Abu Assab Mohammad, Alarman Samia M, Awad Riad M, Hamad Mohammed F, Vicaș Laura Grațiela, Abu Dayyih Wael
Faculty of Pharmacy and Medical Sciences, University of Petra, Amman 11196, Jordan.
Faculty of Pharmacy, Al-Zaytoonah University of Jordan, Amman 11733, Jordan.
Curr Issues Mol Biol. 2024 Nov 1;46(11):12343-12353. doi: 10.3390/cimb46110733.
Diabetes mellitus (DM) is a major global health concern characterized by high blood glucose levels. This study investigates the effects of (cactus) juice and empagliflozin, both alone and in combination, on glycated hemoglobin (HbA1c) levels in healthy and streptozotocin-induced diabetic rats. Eighty Wistar albino male rats were divided into eight groups, with four groups being diabetic. Treatment options included cactus juice, empagliflozin, or both. HbA1c levels were measured at baseline and 100 days later using ELISA. In diabetic and non-diabetic rats treated with cactus juice or empagliflozin, HbA1c levels were significantly reduced, but diabetic rats had significantly lower HbA1c values than non-diabetic rats. The combined treatment provided no additional benefits over individual therapies. These findings indicate that cactus juice and empagliflozin effectively lower HbA1c levels, making their use a promising complementary approach to diabetes management. However, the combined treatment of juice and empagliflozin did not yield additional reductions in HbA1c levels compared to individual treatments, with no significant synergistic effects observed throughout the study period. More research is needed to better understand the clinical applications and mechanisms in humans.
糖尿病（DM）是一种以血糖水平升高为特征的全球主要健康问题。本研究调查了仙人掌汁和恩格列净单独及联合使用对健康大鼠和链脲佐菌素诱导的糖尿病大鼠糖化血红蛋白（HbA1c）水平的影响。80只雄性Wistar白化大鼠被分为八组，其中四组为糖尿病组。治疗方案包括仙人掌汁、恩格列净或两者联合使用。在基线和100天后使用酶联免疫吸附测定法（ELISA）测量HbA1c水平。在用仙人掌汁或恩格列净治疗的糖尿病和非糖尿病大鼠中，HbA1c水平显著降低，但糖尿病大鼠的HbA1c值显著低于非糖尿病大鼠。联合治疗相对于单一疗法没有额外的益处。这些发现表明，仙人掌汁和恩格列净能有效降低HbA1c水平，使其成为一种有前景的糖尿病管理辅助方法。然而，与单一治疗相比，仙人掌汁和恩格列净联合治疗并未使HbA1c水平进一步降低，在整个研究期间未观察到显著的协同作用。需要更多的研究来更好地了解其在人类中的临床应用和机制。
